[Lanreotide acetate may cure cystic dystrophy in heterotopic pancreas of the duodenal wall].
Cystic dystrophy in heterotopic pancreas of the duodenal wall is a rare but benign disease, associated in most of the cases with chronic pancreatitis. Treatment of this disease is controversial. We report here the use of a long-acting somatostatin synthetic stable analogue in the treatment of a cystic dystrophy in heterotopic pancreas of the duodenal wall: a 45-year-old man, hard drinker, was treated successfully during three months with lanreotide acetate; disappearance of cysts was confirmed by a computed tomography two months after the end of treatment.
Basili
E
E
Service d'Hépato-Gastroentérologie, Hôpital de la Timone, CHU, 264, rue Saint-Pierre, 13385 Marseille.
Allemand
I
I
Ville
E
E
Laugier
R
R
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002828:Choristoma / Q000150:complications* / Q000473:pathology; D004378:Duodenal Diseases / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010179:Pancreas; D010181:Pancreatic Cyst / Q000188:drug therapy* / Q000473:pathology; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin